GNLN:NASDAQGreenlane Holdings, Inc. Analysis
Data as of 2026-06-22 - not real-time
$2.57
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Greenlane Holdings (GNLN) trades at $2.57, far below its DCF‑derived fair value of $44.55, suggesting extreme price discount. However, the stock is entrenched in a bearish technical environment – the 20‑day SMA (3.10) sits well under the 50‑day SMA (3.80) and far below the 200‑day SMA (14.46), RSI is at 35 indicating oversold conditions, and the MACD histogram remains negative. Volatility is high (≈81% 30‑day) and beta exceeds 2.5, amplifying price swings. Fundamentally, the company reports negative earnings, a -95% max drawdown, and no dividend, while operating cash flow is negative and margins are in the double‑digit negatives.
The only bright spot is the recent Q1 2026 press release highlighting a 44% increase in BERA‑per‑share holdings, which may hint at incremental upside from its blockchain‑staking activities. Nonetheless, the combination of distressed financials, high beta, and sector‑specific regulatory exposure (tobacco and crypto) makes the stock a high‑risk play despite its apparent undervaluation.
The only bright spot is the recent Q1 2026 press release highlighting a 44% increase in BERA‑per‑share holdings, which may hint at incremental upside from its blockchain‑staking activities. Nonetheless, the combination of distressed financials, high beta, and sector‑specific regulatory exposure (tobacco and crypto) makes the stock a high‑risk play despite its apparent undervaluation.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- Bearish technical pattern (SMA crossover, MACD below signal)
- High short‑term volatility and beta
- Price near immediate support at $2.40
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential upside from BERA staking growth
- Continued earnings weakness and negative cash flow
- Uncertain regulatory landscape for tobacco and crypto
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Massive valuation gap versus DCF fair value
- Strategic pivot toward blockchain infrastructure could improve margins
- Low price‑to‑book (0.03) and price‑to‑sales (0.49) offer deep cushion if turnaround occurs
Key Metrics & Analysis
Financial Health
Revenue Growth-69.50%
P/E Ratio-0.5
ROE-272.88%
ROA-71.83%
P/B Ratio0.0
Op. Cash Flow$-17645000
Free Cash Flow$1.1M
Technical Analysis
TrendBearish
RSI35.7
Support$2.40
Resistance$3.54
MA 20$3.10
MA 50$3.80
MA 200$14.46
MACDBearish
VolumeStable
Fear & Greed Index91.46
Valuation
Fair Value$44.55
GradeUndervalued
TypeValue
Risk Assessment
Beta2.51
Volatility81.01%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.